Presently, the most widely used strategies in tumor immunotherapies that were proven to be effective involve the utilization of immune checkpoint inhibitors such as the CTLA-4 antibody, the PD-1 antibodies and the chimeric antigen receptor T cell (CAR-T), all of which had presented powerful anti-tumor activity in treating a variety of solid tumors and hematologic malignancies [15, 48, 62–64] (Fig. 3). Here, CTLA4 is linked to neoplasm.